Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE772.45-3.35 (-0.43 % )
PREV CLOSE (Rs.) 775.80
OPEN PRICE (Rs.) 782.00
BID PRICE (QTY) 771.10 (35 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 68010
TODAY'S LOW / HIGH (Rs.)761.15 785.30
52 WK LOW / HIGH (Rs.)723.55 986
NSE770.90 -3.85 (-0.5 % )
PREV CLOSE(Rs.) 774.75
OPEN PRICE (Rs.) 778.10
BID PRICE (QTY) 770.90 (452 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2332485
TODAY'S LOW / HIGH(Rs.) 760.50 785.00
52 WK LOW / HIGH (Rs.)723.65 986.1

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 525.34
Dividend Yield(%) 0.65
TTM EPS (Rs.) 28.48
P/E Ratio 27.12
Book Value (Rs.) 364.00
Face Value (Rs.) 2
MCap (Rs. in Mn) 349496.34
Price/Earning (TTM) 20.49
Price/Sales (TTM) 3.31
Price/Book (MRQ) 2.12
PAT Margin (%) 13.33
ROCE (%) 11.72
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Deshbandhu Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
15Feb02-15-2019$Lupin launches Clobazam Oral Suspension Lupin launches Clobazam Oral

Lupin has launched Clobazam Oral Suspension, 2.5mg/mL, having received an approval from the United States Food and Drug Administration (USFDA) earlier. The company's Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/ml. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Clobazam Oral Suspension, 2.5mg/mL had annual sales of $253 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has launched Clobazam Oral Suspension, 2.5mg/mL, having r..
12Feb02-12-2019$Lupin launches Tadalafil Tablets Lupin launches Tadalafil Tab

Lupin has launched Tadalafil Tablets USP 20mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. The company’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly's Adcirca Tablets 20mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has launched Tadalafil Tablets USP 20mg, having received..
11Feb02-11-2019$USFDA completes inspection of Lupin’s Goa facility USFDA completes inspection o

United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Goa manufacturing facility. The inspection was carried out between January 28 to February 8, 2019. The inspection at the Goa facility closed with 2 observations. The observations are procedural in nature and the company is confident of addressing them satisfactorily.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

United States Food and Drug Administration (USFDA) has complete..
08Feb02-08-2019$Lupin rises on getting approval from USFDA for Tadalafil tablets Lupin rises on getting appro

Lupin is currently trading at Rs. 831.00, up by 9.25 points or 1.13% from its previous closing of Rs. 821.75 on the BSE.

The scrip opened at Rs. 829.95 and has touched a high and low of Rs. 832.95 and Rs. 805.85 respectively. So far 92242 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 887.70 and Rs. 805.40 respectively. The current market cap of the company is Rs. 36872.55 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

Lupin has received approval for its Tadalafil tablets USP, 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Adcirca tablets, 20 mg.

The company's Tadalafil tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adcirca tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil tablets, 20 mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 831.00, up by 9.25 points or..
07Feb02-07-2019$Lupin gets approval from USFDA for Tadalafil tablets Lupin gets approval from USF

Lupin has received approval for its Tadalafil tablets USP, 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Adcirca tablets, 20 mg.

The company's Tadalafil tablets USP, 20 mg is the generic version of Eli Lilly and Company's Adcirca tablets, 20 mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil tablets, 20 mg (RLD: Adcirca) had annual sales of approximately $474.3 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has received approval for its Tadalafil tablets USP, 20 m..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit1418.213446.6
Gross Profit 3590.5 17939.3
Operating Profit 8195.622169.8
Net Sales 30928100881.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Hester Biosciences (BSE)
 1408.00 (2.33%)
M.Cap ( in Cr)
1197.77
Ipca Laboratories (BSE)
 805.00 (3.87%)
M.Cap ( in Cr)
10171.34
Alkem Laboratories (BSE)
 1831.35 (1.56%)
M.Cap ( in Cr)
21896.54
Dr. Reddys Lab (BSE)
 2570.00 (0.51%)
M.Cap ( in Cr)
42677.64
Piramal Enterprises (BSE)
 2169.25 (0.40%)
M.Cap ( in Cr)
39922.92
Shareholding Pattern More
MUTUAL FUNDS/UTI 5.69 %
FI/BANKS/INSURANCE 5.38 %
PROMOTERS 46.98 %
NON-INSTITUTION 14.18 %
GOVERNMENT 0.27 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested